Your browser doesn't support javascript.
loading
Challenges and opportunities in neurometabolic disease treatment with enzyme delivery.
Begley, David; Gabathuler, Reinhard; Pastores, Gregory; Garcia-Cazorla, Angeles; Ardigò, Diego; Scarpa, Maurizio; Tomanin, Rosella; Tosi, Giovanni.
Afiliação
  • Begley D; Blood-Brain Barrier Group, King's College London, Strand, London, UK.
  • Gabathuler R; Blood-Brain Barrier Group, King's College London, Strand, London, UK.
  • Pastores G; Medicine, University College Dublin, Belfield, Dublin, Ireland.
  • Garcia-Cazorla A; Neurometabolic Unit. Department of Neurology, Hospital Sant Joan de Déu, CIBERER and MetabERN, Barcelona, Spain.
  • Ardigò D; Chiesi Farmaceutici S.p.A, Parma, Italy.
  • Scarpa M; Regional Coordinating Center for Rare Diseases, Udine University Hospital, Udine, Italy.
  • Tomanin R; Laboratory of Diagnosis and Therapy of Lysosomal Disorders, Dept. of Women's and Children's Health, University of Padova, Padova, Italy.
  • Tosi G; Istituto di Ricerca Pediatrica Città della Speranza, Padova, Italy.
Expert Opin Drug Deliv ; 21(6): 817-828, 2024 Jun.
Article em En | MEDLINE | ID: mdl-38963225
ABSTRACT

INTRODUCTION:

Neurometabolic disorders remain challenging to treat, largely due to the limited availability of drugs that can cross the blood-brain barrier (BBB) and effectively target brain impairment. Key reasons for inadequate treatment include a lack of coordinated knowledge, few studies on BBB status in these diseases, and poorly designed therapies. AREAS COVERED This paper provides an overview of current research on neurometabolic disorders and therapeutic options, focusing on the treatment of neurological involvement. It highlights the limitations of existing therapies, describes innovative protocols recently developed, and explores new opportunities for therapy design and testing, some of which are already under investigation. The goal is to guide researchers toward innovative and potentially more effective treatments. EXPERT OPINION Advancing research on neurometabolic diseases is crucial for designing effective treatment strategies. The field suffers from a lack of collaboration, and a strong collective effort is needed to enhance synergy, increase knowledge, and develop a new therapeutic paradigm for neurometabolic disorders.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Barreira Hematoencefálica / Sistemas de Liberação de Medicamentos Limite: Animals / Humans Idioma: En Revista: Expert Opin Drug Deliv Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Barreira Hematoencefálica / Sistemas de Liberação de Medicamentos Limite: Animals / Humans Idioma: En Revista: Expert Opin Drug Deliv Assunto da revista: FARMACOLOGIA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Reino Unido